Risk increased with candidate-minus-identity loss and selective area was negative.
Support-aware perturbation transfer
Can prediction failure be anticipated before the target outcome is observed?
This status page reports a completed GSE291147 historical replay and the sealed, running GSE306429 replay. It keeps ranking direction, candidate accuracy, decision utility, custody and disease evidence separate.
Platform data remains live
This status page sits beside—not in place of—the Gene Evidence Atlas.
The status page does not remove or replace platform data. Open the released 17,921-gene corpus, inspect stable evidence records, or move directly to typed API objects.
Completed evidence
The GSE291147 direction signal did not produce candidate or decision benefit.
Across 139 items, rho was 0.182363 and selective-risk area was -0.002664. SOURCE_RIDGE loss was 0.917003 versus 0.914852 for identity. Hard support was 2/139; 35% requested coverage achieved 1.44% and decision loss was 0.915605. CPL01 was null and non-triviality failed.
Mean SOURCE_RIDGE loss exceeded the identity reference by 0.002152.
All hard-gated policies selected the same two supported items and remained above identity.
The strict independent-study increment remains zero.
Fixed historical replay update
One replay is complete; the chemical replay is running under its sealed contract.
GSE291147 scored all 139 items once. GSE306429 has a sealed source prediction package and one-time authorization for exactly 52 archives before 44 plate computations and equal-route scoring across seven routes and 627 route-items.
Source: 184,414 A375 cells, 96 items, 2,909 genes and 56 supported items. No target score exists yet.
Official GEO record ↗Direction passed; mean candidate loss, decision loss, CPL01 and non-triviality did not support deployment.
Official GEO record ↗No A375 source checkpoint or target score was produced, and no substitute model was introduced.
The GSE306429 route and aggregate results will be released whether favorable, null or adverse.
Disease boundary
DMD is a motivation and evidence-triage use case, not an efficacy result.
Directly measured outcomes remain 0/21 for the current DMD candidate set. Restoring DMD as a central efficacy claim requires a separate disease-matched functional validation program.